Equillium, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals

Other Names/Subsidiaries

  • Attenuate Biopharmaceuticals, Inc.
See more in Biomedtracker

Latest on Equillium, Inc.

Scrip

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss

 
• By Alaric DeArment

Equillium is hoping that unmet medical need and long-term efficacy will persuade the US Food and Drug Administration to approve itolizumab for acute graft-versus-host disease (aGVHD) despite its Phase

Scrip

Eight Recent Deals Tapping AI/ML For R&D

 
• By Joseph Haas

As the improvements made possible with artificial intelligence and machine learning for biopharmaceutical research and development become clear, deal making in the space has skyrocketed. S&P Global pr

Scrip

J.P. Morgan Day One: Novartis Reveals Two Deals, Pfizer's Bad Year, Bristol's Wobbly Growth

 
• By Scrip Team

Novartis Debuts Two Deals While Johnson & Johnson had the day’s largest acquisition with the $2bn offer for antibody-drug conjugate specialist Ambrx, Inc. (Also see " J&J Makes Its Biggest

Scrip

Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Taps Anima’s mRNA Platform, Immu